6533b831fe1ef96bd1298770
RESEARCH PRODUCT
Triptans and CGRP blockade - impact on the cranial vasculature.
Silvia BenemeiFrancesca CorteseAlejandro Labastida-ramírezFrancesca MarcheseLanfranco PellesiMichele RomoliAnne Luise VollesenChristian LamplMessoud AshinaOn Behalf Of The School Of Advanced Studies Of The European Headache Federation (Ehf-sas)subject
0301 basic medicineMigraine DisordersCalcitonin gene related peptide – CGRPNeuropeptidelcsh:MedicineMigraine modelsReviewTriptansReview ArticleCalcitonin gene-related peptide03 medical and health sciences0302 clinical medicineJournal ArticlemedicineHumansMigraine treatmentReceptorbusiness.industryTriptans Calcitonin gene related peptide – CGRP Anti-CGRP (receptor) monoclonal antibodies – mAbs Middle meningeal artery Middle cerebral arteries Migraine models Magnetic resonance angiography (MRA)Anti-CGRP (receptor) monoclonal antibodies – mAbsTrigeminovascular systemlcsh:RTriptansGeneral MedicineMiddle meningeal arterymedicine.diseaseTryptamines3. Good healthMagnetic resonance angiography (MRA)Middle cerebral arteries030104 developmental biologyAnesthesiology and Pain MedicineMigraineAnesthesiaNeurology (clinical)SerotoninbusinessNeuroscience030217 neurology & neurosurgerymedicine.drugReceptors Calcitonin Gene-Related Peptidedescription
Abstract The trigeminovascular system plays a key role in the pathophysiology of migraine. The activation of the trigeminovascular system causes release of various neurotransmitters and neuropeptides, including serotonin and calcitonin gene-related peptide (CGRP), which modulate pain transmission and vascular tone. Thirty years after discovery of agonists for serotonin 5-HT1B and 5-HT1D receptors (triptans) and less than fifteen after the proof of concept of the gepant class of CGRP receptor antagonists, we are still a long way from understanding their precise site and mode of action in migraine. The effect on cranial vasculature is relevant, because all specific anti-migraine drugs and migraine pharmacological triggers may act in perivascular space. This review reports the effects of triptans and CGRP blocking molecules on cranial vasculature in humans, focusing on their specific relevance to migraine treatment.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-10-10 | The journal of headache and pain |